Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H3Cl3O4P.Na |
Molecular Weight | 251.365 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OP([O-])(=O)OCC(Cl)(Cl)Cl
InChI
InChIKey=WFKJEZKHPGDCRK-UHFFFAOYSA-M
InChI=1S/C2H4Cl3O4P.Na/c3-2(4,5)1-9-10(6,7)8;/h1H2,(H2,6,7,8);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C2H3Cl3O4P |
Molecular Weight | 228.376 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Triclofos is primarily indicated in conditions like Insomnia, and can also be given in adjunctive therapy as an alternative drug of choice in Nausea, vertigo, labyrinthine disorders. It is also used sedate people suffering from anxiety or tension before medical investigations. Triclofos is converted to Trichloroethanol in the body .This act on brain and produces sleep. Trichloroethanol decreases time taken to fall asleep and lengthen the sleep. Triclofos is most commonly used agent for sedation in
neonates as well as in older infants and children in Japan.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRICLOS Approved UseTriclofos is used to treat sleeping problems (insomnia) in people. It is also used sedate people suffering from anxiety or tension before medical investigations. |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
65% |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Iatrogenic encephalopathy. | 1970 May |
|
A pediatric sedation/anesthesia program with dedicated care by anesthesiologists and nurses for procedures outside the operating room. | 2004 Jul |
|
An analysis of oxygen consumption and oxygen delivery in euthermic infants after cardiopulmonary bypass with modified ultrafiltration. | 2004 Oct |
|
Non-epileptic pedaling-like movement induced by triclofos. | 2004 Oct |
|
[Severe airway obstruction relieved by sedation using sevoflurane in a pediatric patient with tracheobronchomalacia]. | 2005 Feb |
|
Efficacy and adverse effects of rectal thiamylal with oral triclofos for children undergoing magnetic resonance imaging. | 2006 Apr |
|
Transient administration of triclofos sodium is helpful in minimizing anticonvulsants under polypharmacy. | 2006 Dec |
|
A method for screening for various sedative-hypnotics in serum by liquid chromatography/single quadrupole mass spectrometry. | 2006 Feb 10 |
|
Comparison of solvent mixtures for pressurized solvent extraction of soil fatty acid biomarkers. | 2008 Oct 19 |
|
Proteomic analysis of regenerating mouse liver following 50% partial hepatectomy. | 2009 Dec 29 |
|
Modeling hydroxyl radical distribution and trialkyl phosphates oxidation in UV-H2O2 photoreactors using computational fluid dynamics. | 2010 Aug 15 |
|
Procedural sedation analgesia. | 2010 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_9972.html
The usual adult dose as a hypnotic is 1 to 2 g orally at night. A suggested hypnotic dose for children 1 month to 1 year of age is 25 to 30 mg/kg; children aged 1 to 5 years may be given single doses of 250 to 500 mg, and children aged 6 to 12 years may be given single doses of 0.5 to 1 g.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:33:48 UTC 2022
by
admin
on
Fri Dec 16 17:33:48 UTC 2022
|
Record UNII |
9F90KA5Q8U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB15606MIG
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
DBSALT001424
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
23677832
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
M11090
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | Merck Index | ||
|
230-652-3
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
CHEMBL1201317
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
DTXSID60993262
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
7246-20-0
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
9F90KA5Q8U
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | |||
|
104696
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY | RxNorm | ||
|
C66630
Created by
admin on Fri Dec 16 17:33:48 UTC 2022 , Edited by admin on Fri Dec 16 17:33:48 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |